Respiratory
Chiesi has been developing medicines to treat respiratory disease for more than 30 years. Thanks to modern treatments, patients with asthma or chronic obstructive pulmonary disease (COPD) are able to live more active lives with greater self-confidence. After all, to breathe is to...
Neonatology
By around the completed 37th week of pregnancy, babies will have developed to the point that they are able to survive outside the womb. Any child born before this point is referred to as premature. Thanks to the enormous progress in neonatology (Greek: “the study of newborns”), which...
Rare Diseases
The European Union defines a disease as rare if it affects no more than 5 in 10,000 people in the EU. Up to 8,000 rare diseases exist worldwide. Around four million people live with a rare disease in Germany alone; in the EU the number is estimated at 30...
Transplantation
In cases where an essential organ fails and it is not possible to restore its function, a transplant often provides the only chance of survival. Perhaps also a chance at a new outlook on life. Since the first successful kidney transplant was carried out by Joseph E. Murray in the US in 1954,...
Home
-
About Chiesi
The Chiesi Group
Chiesi Farmaceutici S.p.A.is an international, privately-managed pharmaceutical company based in Parma, Italy. Chiesi dedicates itself to the research, development and sales of innovative, therapeutic prescription products in the areas of...
Mission & Values
Our aim is to be recognised as a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life.
We wish to maintain a high quality entrepreneurial team characterised by self-confidence and a collaborative...
Sustainability Report
At Chiesi, we recognise the importance of viable and sustainable business models for our future. We make commitments that are clearly formulated and measurable, and we report transparently on our progress every year.
Sustainability Report 2023 Alle Berichte (Chiesi.com)
lhon
-
Sustainability
The Power of Shared Value: How Chiesi lives sustainability
“We want to consider the economic, social and ecological aspects of our actions together. The economic success of our company must be linked to social added value – in other words, it must generate shared...
Management
-
Imprint
Chiesi GmbH
Gasstraße 6
22761 Hamburg
Contact:
Tel.: +49 (0)40 897 24-0
Fax: +49 (0)40 897 24-212
info.de(at)chiesi.com
Rrepresentative Managing Director:
Leonardo...
Our Partners
To ensure the best possible medical care for our patients, we cannot and do not want to act alone. One pillar of our work is cooperation with strong partners, with whom we work together on improvements for patients, society, and the environment.
Compliance with...
Research & Development
Being able to offer innovative treatment options and thus improve the health and lives of our patients is the engine that drives us. For this reason, research and development (R&D) is not only important to Chiesi as a company with a technological focus but it is also essential to us as a...
Customer Service
Dear Customer,
Full-line pharmaceutical wholesalers (PHAGRO), public pharmacies, hospital and supply pharmacies, doctors and patients – all of you are our customers and we are happy to help you. It is our aim to offer effective solutions and to manufacture and supply high-quality...
Service for Patients
Dear Patients,
Our guides provide a great deal of useful information about asthma, allergies, transplants and mucoviscidosis for interested parties and those affected by these conditions. In addition, you can also find addresses for self-help groups, healthcare portals and...
Contacts
The following contact details must be used for your comments or questions concerning our Company and cannot be used to report adverse event to our products or for medical questions. For this kind of reporting, please refer to PHARMACOVIGILANCE. For applications, please use our contact...
CHIESI FOUNDATION ONLUS
Founded in 2005, the Chiesi Foundation is a non-profit organization, expression of the Chiesi Farmaceutici's social responsibility.
In the Foundation, ethics and knowledge merge with the aim to promote health and alleviate the suffering of patients affected by respiratory and neonatal...
job offers
Discover our job offers. We look forward to receiving your application!
TO OUR GERMAN CAREER PORTAL
TO OUR INTERNATIONAL CAREER PORTAL
Students
Would you like to put your theoretical knowledge into practice and gain work experience while you are still studying? Get to know the processes of an internationally operating pharmaceutical company as part of an internship or a working student position.
Contact our HR...
Our Commitment
At Chiesi, social obligation isn’t just a buzzword; it is a mission statement. We support various organisations, and our employees are involved in diverse social and community projects.
For example, our colleagues helped to renovate, paint and refurbish the...
Healthcare Professionals
To gain access to more detailed information, we ask you to register with us using DocCheck.
We also ask for your understanding that under the German Drug Advertising Act, only medical professionals may be granted access to this more detailed information.
Log-In erfolgreich, Herzlich Willkommen!
Thank you for logging in. Please wait, you will soon be redirected.
Media contact
Chiesi GmbH
Gasstraße 6 22761 Hamburg (Germany)
Your contact:
E-mail service
-
unsubscribing
Thank you for your interest in our e-mail service!If you no longer wish to use our e-mail service, please enter your e-mail address and click on „unsubscribe”.
We are consistently trying to improve our services and would be pleased to know your reason for unsubscribing...
Code of Conduct Chiesi GmbH
Chiesi GmbH is a company in the pharmaceutical industry. We sell innovative products, and our goal is to promote the research and development of new products and treatment methods as well as to improve the quality of medical standards for the good of the patient. We therefore have diverse links...
Pharmacovigilance
Chiesi Farmaceutici has a system of pharmacovigilance in order to assume liability for our medicinal products (whether marketed or under clinical development) and to take appropriate actions when necessary. We ensure that all information relevant to the benefit-risk ratio of our medicinal...
Sitemap
-
Data privacy / Cookies
Datenschutzhinweise
Wir freuen uns über Ihren Besuch auf unserer Website und Ihr Interesse an unserem Unternehmen und unseren Produkten. Wir respektieren die Privatsphäre eines jeden, der diese Website besucht. Die Chiesi GmbH, Gasstr. 6, 22761 Hamburg, eingetragen im Handelsregister...
Download Area
Information to the Chiesi Group and the annual report can be found at www.chiesi.com.
News for Healthcare Professionals
To gain access to more detailed information, we ask you to login by using DocCheck.
We also ask for your understanding that under the German Drug Advertising Act, only medical professionals may be granted access to this more detailed information.
General terms and conditions
Allgemeine Geschäftsbedingungen der Chiesi GmbH für öffentliche Apotheken (Stand 01.01.2022)Allgemeine Geschäftsbedingungen für den pharmazeutischen Großhandel (Stand 01.01.2022)
Allgemeine...
Pharmacies
In the interests of good and collaborative partnership, we want to ensure optimal stocks of our products.
Therefore, we provide the following returns regulations (the returns regulations are part of our general terms and conditions.
Asche Basis® formulations
Asche Basis® series
Asche Basis® Creme (cream) 50 ml, 100 ml, 1000 ml
for dry and sensitive skin
Water content 68 %
pH value: 5,5 – 6,5
Shelf life after opening: 6 months
(Ingredients - INCI names: aqua, petrolatum, paraffinum liquidum, stearyl alcohol,...
Asthma guide
One of Chiesi GmbH’s main areas of focus is on providing medications to treat respiratory diseases. This includes drugs to treat asthma. Alongside our range of treatment options for doctors, we want to help patients and their families better understand asthma as a disease, to enjoy as much...
Allergy guide
Allergy – a widespread illness
Allergies are widespread. Virtually everyone knows somebody among their family members or acquaintances who is affected by a pet hair allergy, neurodermatitis, hay fever or asthma. Because allergies have been on the increase for many years now,...
Cystic Fibrosis guide
Cystic fibrosis is the most common congenital metabolic disease that is currently incurable. Those affected suffer, among other things, from thick mucus in the lungs, resulting in chronic coughing and frequent and protracted lung infections. Cystic fibrosis is a systemic disease. This means that...
Patient organisations
Contributions to patient organizations
The focus of our activities is on patients! Against this background, Chiesi regularly supports the statutory tasks of patient self-help organizations with the aim of improving the quality of life and care of affected people,...
Service for Healthcare professionals
The HCP portal from Chiesi: ChiesiConnectwww.chiesiconnect.deMore websites for healthcare professionals:
Respiratory
www.nexthaler.de (product website)
Transplantation
www.touchTx.de (product website)
Rare...
Neonatology Guide
Eltern von frühgeborenen Babys benötigen vielseitige Unterstützung, weit über die ersten Wochen in der Klinik hinaus. Fehlt zu Hause plötzlich das Team aus Ärzt*innen und Pfleger*innen, fühlen sich Eltern oft auf sich allein gestellt und haben viele Fragen zur...
Login
-
Transplant Guide
Anyone who has had a kidney or liver transplant often has to find their way around in everyday life again afterwards. Many questions, even about seemingly simple procedures, are then completely normal. Are you waiting for a suitable donor organ or have you just had an organ transplant? What happens...
Guide COPD
COPD is a chronic obstructive pulmonary disease that affects approximately five to ten percent of adults over the age of 40 in Germany.
The generic term chronic obstructive pulmonary disease covers a number of diseases of the lungs. They include chronic bronchitis, a very common disease...
SpeakUp&BeHeard
-
Compliance
It is extremely important to us to ensure trustworthy and ethical cooperation. As such, we have developed internal corporate values and guidelines on conduct and leadership, and we operate and act in accordance with these. We also consider social responsibility to be crucial: we support research...
Transparency
Close professional exchange as well as trustful collaboration with a variety of stakeholders, have a beneficial impact on the quality of patient care. Alongside other EFPIA (European federation of pharmaceutical industries and associations) members, Chiesi is committed to the principle of...
Development @ Chiesi
At Chiesi, we develop your skills and strengthen our teams for our mutual success.
Unleash your superpowers: learning and leadership at Chiesi
Learning
Our offer for the personal development of our employees...
Trimbow 8759 PT
-
Application process
What can you expect during the application process at Chiesi?
Graduates / Young Professionals
Have you successfully completed your studies or are you about to do so? Then start with one of our trainee programs or join us directly. It is important to us to provide you with structured support and to prepare you for your professional career at Chiesi.
You can contact our HR team...
Professionals
Entry as a professional
Are you looking for a challenge with the opportunity to shape your career in the sales, scientific, regulatory or strategic area?Whether you are a specialist or a manager, we look forward to meeting you! Growth and change are the hallmarks of our company. Grow...
Anti-bribery Policy
The Chiesi Group pursues a zero-tolerance approach to bribery and corruption in relation to working alongside each business partner. It directs its business activities in accordance with the principles of fairness, honesty, transparency and integrity. Furthermore, relevant national and...
Thank for your submission
Vielen Dank für Ihre Reklamationsmeldung, die wir nach Eingang des Musters umgehend bearbeiten werden.
Reklamationsschein
-
resticted-page
-
Code of Conduct Chiesi Group
The Chiesi Company acts according to ethical principles: We want to strengthen our values and base our activities on this particular value system. The observance to these values enables us to operate successfully in business, to protect our society and environment and to develop our...
B Corp
Our commitment for sustainability
While sustainability has always been important for Chiesi, today it is part of our strategic plan. It means we are committed to improve the quality of life of patients, to protect the planet and its inhabitants, to support our communities, to favour the...
FAQs
-
Working at Chiesi
Open communication, working independently, solution-oriented teamwork and fair cooperation - at Chiesi every single person is essential. We value each employee with their individual strengths and want to support them in their development. That is one of our highest goals.
Our understanding as an employer
Our understanding as an employerBeing an attractive employer!
We want to be an attractive employer for our present and prospective employees – that’s what we work for every day. Our employees are highly qualified, think entrepreneurially and contribute to our success story every day...
Your opportunities to join us
We offer you exciting opportunities: discover the wide range of entry-level opportunities at Chiesi.
Your opportunities to join us
The Chiesi Group has more than 7,000 employees worldwide, around 400 of whom are involved in the daily operations in Germany. They are highly...
Benefits
At Chiesi Germany, the well-being of our employees is our top priority. We promote a healthy work-life balance with a wide range of benefits and take the needs of our employees into account.
Fachkreiseservice demo
-
Mail Service Pneumologie
-
Code of Interdependence
The Chiesi Group has been B Corp certified since 2019. As B Corp, we are part of a global community of companies that meet high social and environmental standards.
For this reason, we have developed the Chiesi Code of Interdependence ("Code of Conduct for Chiesi's Suppliers"). It...
Instagram Highlights
-
atemweg
-
The Digital Therapy Extension
-
Certificates AeroChamber Plus* Flow-Vu*
Here you will find the certificates of conformity for the AeroChamber Plus* Flow-Vu* inhalation aids by Trudell Medical International.
DoC RespiChamber mit Mundstück
DoC RespiChamber Masken
DoC AeroChamber mit Mundstück Kinder und Erwachsene
DoC...
Pharmacy-only OTC products
-
Cosmetics
-
NHCO dietary supplements
-
Ability to Deliver
-
TRANSLATE with x
English
Arabic
Hebrew
Polish
Bulgarian
Hindi
Portuguese
Catalan
Hmong Daw
Romanian
Chinese Simplified
Hungarian
Russian
Chinese...
Datenschutzerklärung für Teilnehmende an Online-Umfragen
-
datenschutzerklaerung fuer fachkreise
-
Temperature deviation requests
Dear Pharmacy Team,
due to the Ukraine crisis and the resulting possible blackouts, pharmacies have been asked to deal with the issue of how to handle temperature-sensitive products in the event of a power outage.
If Chiesi products are affected by...
Datenschutzhinweise für Geschäftskund*innen und für diese handelnde Ansprechpersonen
-
Dr. Matthias Weide voted as BPI board memeber
-
Trimbow for Asthma
Press release Neonatology of 17.05.2017
Press release Respiratory of 23.05.2017
Press release Respiratory of 27.06.2017
-
-
-
-
Weltfrühgeborenentag 2022: Feiern Sie mit uns 30 Jahre Nähe zu Frühgeborenen!
-
-
-
-
-
Chiesi awarded “Top Employer” for the eighth time
-
-
-
-
Jubiläum: Chiesi erhält den Titel "Top Employer" des Jahres zum zehnten Mal in Folge
-
-
-
-
-
Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification
-
Hamburg breathes deeply – free pulmonary function testing for all
-
-
Chiesi Group confirms positive trend to date for 2019
-
-
-
-
Happy New Year 2020
-
Chiesi Group announces establishment of new global rare diseases division
Chiesi awarded „Great Place to Work 2020“
-
-
-
Chiesi "Top Employer" for the ninth time in a row
Chiesi Group increases support measures and announces new funds for patients and healthcare providers in response to COVID-19 pandemic in Italy
Chiesi outlines €350 million investment and announces first carbon minimal pressurised Metered Dose Inhaler
-
-
-
New Job platform
Chiesi issues code Code of Interdependence
-
-
Spendenkampagne von Chiesi: Verantwortung zeigen in kritischen Zeiten
-
Moderna und Chiesi Gruppe geben Zusammenarbeit zur Forschung und Entwicklung von mRNA-Therapeutika für pulmonale arterielle Hypertonie (PAH) bekannt
We ACT! Ein Tag im Zeichen der Nachhaltigkeit bei Chiesi
-
-
Chiesi unterzeichnet Charta der Vielfalt
-
-
-
Kaia Health und die Chiesi Gruppe kündigen eine strategische Partnerschaft zur Vermarktung der App „COPD Therapie – Kaia“ auf europäischen Märkten an
Chiesi launches “The Art of Caring”
-
-
Humane Care with Dignity: Photo project visualizes the stories behind the mask
European marketing authorization for the treatment of moderate to severe asthma
Rare Disease Day 2021
International Womans Day
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
Inhalierhilfen (Spacer) neu im Portfolio von Chiesi
Virtuelle Fotoausstellung würdigt Geschichten von Menschen aus Pflegeberufen
Chiesi Group: performance is up in 2020
Welt-Asthma-Tag: Luft ist unser wertvollstes Gut
Chiesi erhält europäische Zulassung für Trimbow® im Trockenpulverinhalator NEXThaler® (Beclometason/Formoterol/Glycopyrronium)
New organisational order for the Chiesi Foundation
Chiesi Group calls for ActionOverWords in the fight against climate change
Organspende: Ein Zeichen von Solidarität
Diversität und Inklusion sind ein großer Teil der Unternehmenskultur von Chiesi
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
Change at the top of the Chiesi Germany Management Board
-
World Mitochondrial Disease Week
Chiesi receives positive ESG rating from independent rating agency Cerved
-
-
Spannende Online-Podiumsdiskussion zum Thema Klimawandel und Atemwegserkrankungen
Chiesi verfolgt Maßnahmen für eine gesündere, nachhaltigere Zukunft
World Prematurity Day 2021: A purple sign for the little ones
-
Chiesi erneut mit Trainee-Siegel gekürt
Wechsel des Chiesi-Logistikdienstleisters zum 01. Januar 2022
Weihnachtsgrüße von Chiesi
Chiesi and UCB enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases
Chiesi GmbH begeistert erneut als „Top Employer”
“Helping the World to Breathe” - Chiesi Group among the protagonist of the ATS docuseries
Global Rare Disease Day 2022: Mehr Aufmerksamkeit für Betroffene
World Kidney Day
Ein farbenfrohes Zeichen für seltene Erkrankungen
Recycling bei Chiesi
Kodex für Interdependenzen: Für mehr nachhaltige Zusammenarbeit
Unsere Erde, unsere Gesundheit – das Motto des diesjährigen Weltgesundheitstages
Chiesi-Gruppe setzt Wachstum 2021 weiter fort
Außervertriebnahme von Manyper® und Vivace®
SIGNS: Live-Webinar zu Seltenen Erkrankungen
Jubiläum: Chiesi feiert 20-jähriges Bestehen in Deutschland
Auf die Plätze, fertig, los! Chiesi startet beim HafenCity Run
Chiesi erwirbt innovatives Biologika-Portfolio zur potenziellen Behandlung von seltener Erkrankung PAH
Chiesis Aktivwoche: Sport für einen guten Zweck
Arbeitsgemeinschaft Therapie Seltene Erkrankungen (ATSE) launcht eigene Webseite
Chiesi packt an: We ACT Day 2022
rare Disease Day 2023: Chiesi supports #wiedu
Erstes Dosieraerosol mit reduziertem Treibhauseffekt ist auf Kurs, zum Wohle der Patient*innen und der Umwelt
Chiesi wird als B Corp rezertifiziert und setzt sich neue, strengere Ziele für Maßnahmen bis 2025
Lunge fürs Leben: Welt-COPD-Tag 2022
Orders over the turn of the year
Chiesi at Handelsblatt Jahrestagung 2022 „Health The Digital Future“
From cells to packaging, the Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
Chiesi wünscht frohe Festtage
-
Chiesi appoints Giuseppe Accogli as new Group CEO
WeACT Con: new leading congress on health, environment and sustainability
-
Chiesi Germany participates in B Corp Month: WeGoBeyond
Kaia COPD: Digital therapeutic with measurable success
Chiesi Global Rare Diseases und Protalix BioTherapeutics erhalten positive CHMP-Empfehlung für Pegunigalsidase Alfa zur Behandlung von Morbus Fabry
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
2022 for Chiesi: The Group’s international growth continues
Chiesi receives the akg siegel for the third time in a row
WeACT Con 2023
-
Chiesi supports the ELHK Rare Disease Symposium
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
Interview mit Lea (Brand & Customer Managerin Rare Diseases) zur neuen Morbus Fabry Website
WeACT Con review available
Chiesi
-
Chiesi Group mid-year financial results demonstrate strong growth for 2023
Availability holidays 2023 2024
WE ACT Day 2023
World Prematurity Day 2023
World Prematurity Day 2023: Awareness for the little ones
-
-
Chiesi is again a Top Employer
Im Interview mit unserer Shared Value and Sustainability Business Partnerin
March is international B Corp Month
Two new members of the Chiesi management team
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
Virtual Kick-off Event for More Lung Sports in Germany
We ACT Con 2025
WeACT Con 2024: The forum for sustainability in the healthcare sector
Chiesi erreicht bei der Entwicklung von Dosieraerosolen mit minimiertem CO2-Fußabdruck neuen Meilenstein
Verschwendung reduzieren, Prävention stärken: Mutige Schritte für mehr Nachhaltigkeit im Gesundheitswesen nötig
2023 Finanzbericht der Chiesi Gruppe
Kaia COPD: DiGA erhält keine dauerhafte Listung vom BfArM
Neue Vorteile bei Chiesi Deutschland: Für eine bessere Vereinbarkeit von Familie und Beruf!
Der WeACT Con Film 2024 ist live
Sustainability Report 2023 von Chiesi
Wechsel an der Spitze der Chiesi GmbH
Lena Harmann new member of the Chiesi Leadership Team
Deine Lunge – Dein Event – der Tag für die Lungengesundheit von Chiesi
We Act Day 2024
Das neue Biotech Center of Excellence der Chiesi Gruppe bringt die Zukunft der Medizin nach Parma
Ein Meilenstein für die Lungengesundheit
Nachhaltigkeitskommunikation - der Shared Value Elevator Pitch
Zum Schutz des Planeten Handeln - im Interview mit unserer Shared Value and Sustainability Business Partnerin
Report – Chiesi setzt sich für die Zukunft der Versorgung selten Erkrankter ein
Erfolgreich und zufrieden im Arbeitskontext - ein Interview mit unserer Head of People Development
Availability holidays 2024 2025
Nachhaltiges Wachstum und wirtschaftlichen Erfolg vereinbar machen
World Prematurity Day on 17 November
Mit verschiedenen Maßnahmen die individuellen Bedürfnisse der Patient*innen bestmöglich erfüllen - ein Interview mit unserer National Patient Advocacy Managerin
Great Place To Work and Fortune Name Chiesi Group No. 23 in 2024 World’s Best Workplaces™ List
Chiesi unterzeichnet Aktionsbündnis "Patientinnenfreundliche und klimabewusste Verordnung von Inhalativa"
Chiesi has once again been recognized as Top Employer!
Fresh Design for Asche Basis
Nachbericht: Patientenzentrierung und zukunftsorientierte Versorgung für Seltene Erkrankungen
Diversität als Stärke
Chiesi Group stärkt Innovation in Europa: Keynote von Leonardo Mallmann
Chiesi Gesundheitswoche: Für das Wohl unserer Mitarbeitenden
Chiesi Acquires New Manufacturing Site in Nerviano (Milan) with a Strategic €430 Million Investment To 2030 to Drive Global Growth
WeACT Con 2025 - Das Forum Nachhaltigkeit im Gesundheitswesen
Three years of WeACT Con: Sustainability in the healthcare sector - much achieved, much still to do
Updated Code of Interdependence
Beclorhinol® aquosum 50 micrograms Nasal spray, Suspension
Bramitob® 300 mg/4 ml nebulizer solution
Budiair® 200 micrograms Compressed gas inhalation, solution
ELFABRIO® 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Curosurf® 120 mg/240 mg
Envarsus 0,75 mg/1 mg/ 4 mg Sustained-release tablets
FOSTER® 100/6 micrograms pressurized inhalation solution
Raxone® 150 mg Filmtabletten
FOSTER® NEXThaler® 100 micrograms /6 micrograms per dose, powder for inhalation
Forair® 12 micrograms Pressurized gas inhalation, solution
Bronchitol® 40 mg inhalation powder, hard capsules
Otobacid® N Ear drops, solution
Peyona® 20 mg/ml Solution for infusion and oral solution
Asche Basis®
schnupfen endrine ® drops 0,1 %, spray 0,1 %
Sanasthmax® 400 micrograms/1 ml Suspension for nebulizer
FOSTER® 200/6 micrograms pressurized inhalation solution
FOSTER® NEXThaler® 200 micrograms /6 micrograms per dose, powder for inhalation
Trimbow® 87/5/9 Mikrogramm Druckgasinhalation, Lösung
Budapp nasal® 50 Mikrogramm Nasal spray, Suspension
PROCYSBI® 25 mg/75mg
Trimbow® 172/5/9 micrograms pressurized inhalation solution
Lamzede® 10 mg powder for solution for infusion
Quinsair® 204 mg nebuliser solution
AeroChamber Plus* Flow-Vu* mit Mundstück – ab 5 Jahren
AeroChamber Plus* Flow-Vu* mit Maske – ab 5 Jahren
AeroChamber® Plus* Flow-Vu* mit Mundstück für Kinder – ab 5 Jahren
RespiChamber* HOSPITAL - mit Mundstück
AeroChamber Plus* Flow-Vu* mit Maske für Säuglinge – 0-18 Monate
AeroChamber Plus* Flow-Vu* mit Maske für Kinder – 1-5 Jahre
AeroChamber Plus* Flow-Vu*
Ferriprox® 100 mg/ml Lösung zum Einnehmen
Ferriprox® 500 mg/1000 mg Film tablets
Trimbow® 88 Mikrogramm/5 Mikrogramm/9 Mikrogramm Pulver zur Inhalation im NEXThaler®
AeroChamber Plus* Flow-Vu* mit kleiner Maske für Erwachsene
Hair+
Derma-AS+
Cellu-Step
My-Balance+
Vision+
Retin-A+
Lacto+
ETD Man+
Ortho+
Meno+
Myalepta 3mg/ 5,8 mg/ 11,3 mg
Lojuxta
Filsuvez Gel
